All Stories

  1. Using Wearable Device and Machine Learning to Predict Mood Symptoms in Bipolar Disorder: Development and Usability Study
  2. Using Wearable Device and Artificial Intelligence to Predict Mood Symptoms in Bipolar Disorder (Preprint)
  3. Dose-tapering trajectories in patients with remitted psychosis undergoing guided antipsychotic reduction to reach minimum effective dose
  4. The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis
  5. The changes of parental functioning of the patients with bipolar disorder and major depression since discharging from hospital: A longitudinal study
  6. Follow-up of subjects labelled with putative pre-psychotic states: Viewed from a transdiagnostic clinical high-at-risk mental state (CHARMS) paradigm
  7. Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship
  8. Characterization of clinical features and comorbidities between bipolar affective disorder with and without depressive episodes
  9. Dysregulated affective arousal regulates reward-based decision making in patients with schizophrenia: an integrated study
  10. Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists’ Attitudes in Taiwan
  11. Detection of advanced brain aging in schizophrenia and its structural underpinning by using normative brain age metrics
  12. Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
  13. A quarter of century after: The changing ecology of psychiatric emergency services
  14. Challenging the Minimum Effective Antipsychotic Dose During Maintenance: Implications From 10-Year Follow-Up of First Episode Psychosis
  15. The experiences of family resilience from the view of the adult children of parents with bipolar disorder in Chinese society
  16. Protocol of guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis based on pragmatic design
  17. Mismatch negativity and P3a in drug-naive adults with attention-deficit hyperactivity disorder
  18. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?
  19. P50, N100, and P200 Auditory Sensory Gating Deficits in Schizophrenia Patients
  20. Clinical implications of oxidative stress in schizophrenia: Acute relapse and chronic stable phase
  21. Mismatch negativity to different deviant changes in autism spectrum disorders: A meta-analysis
  22. Social cognition in schizophrenia: A network-based approach to a Taiwanese version of the Reading the Mind in the Eyes test
  23. P50-N100-P200 sensory gating deficits in adolescents and young adults with autism spectrum disorders
  24. Stigmas toward psychosis‐related clinical features among the general public in Taiwan
  25. Clinical characteristics and outcomes associated with weekend admissions to psychiatric wards in Taiwan
  26. Points that need attention in quantitative EEG gamma synchronization
  27. Transcriptome Changes in Relation to Manic Episode
  28. Auditory Event-Related Potentials in Antipsychotic-Free Subjects With Ultra-High-Risk State and First-Episode Psychosis
  29. Genetic associations and expression of extra-short isoforms of disrupted-in-schizophrenia 1 in a neurocognitive subgroup of schizophrenia
  30. Sex as a Moderating Factor in the Relationship Between Hippocampal Volume and Sensory Gating in Patients With Schizophrenia
  31. Advanced Paternal Age and Early Onset of Schizophrenia in Sporadic Cases: Not Confounded by Parental Polygenic Risk for Schizophrenia
  32. Points that need attention in auditory N100 gating research in schizophrenia
  33. Association between mismatch negativity and voxel-based brain volume in schizophrenia
  34. Trajectories after first-episode psychosis: Complement to ambiguous outcomes of long-term antipsychotic treatment by exploring a few hidden cases
  35. T182. SHARED AND DISTINCT ALTERATIONS IN THE WHITE MATTER TRACTS OF REMITTED AND NON-REMITTED PATIENTS WITH SCHIZOPHRENIA
  36. Comparative effect of antipsychotics on risk of self‐harm among patients with schizophrenia
  37. Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia
  38. Mismatch Negativity and P3a in Adolescents and Young Adults with Autism Spectrum Disorders: Behavioral Correlates and Clinical Implications
  39. Impacts of Electroconvulsive Therapy on 1-Year Outcomes in Patients With Schizophrenia: A Controlled, Population-Based Mirror-Image Study
  40. Polygenic risk for schizophrenia and neurocognitive performance in patients with schizophrenia
  41. Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database
  42. Misfortune may be a blessing in disguise: Fairness perception and emotion modulate decision making
  43. Metformin-induced acute dystonia in a schizophrenic patient treated with sulpiride and clozapine
  44. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder
  45. Haplotypes of the D-Amino Acid Oxidase Gene Are Significantly Associated with Schizophrenia and Its Neurocognitive Deficits
  46. Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue
  47. Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics
  48. Primary and secondary alterations of white matter connectivity in schizophrenia: A study on first-episode and chronic patients using whole-brain tractography-based analysis
  49. Automatic whole brain tract-based analysis using predefined tracts in a diffusion spectrum imaging template and an accurate registration strategy
  50. Initiating long-acting injectable antipsychotics during acute admission for patients with schizophrenia – A 3-year follow-up
  51. Effects of affective arousal on choice behavior, reward prediction errors, and feedback-related negativities in human reward-based decision making
  52. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial
  53. Neurocognitive functioning of subjects with putative pre-psychotic states and early psychosis
  54. Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms
  55. Altered integrity of the right arcuate fasciculus as a trait marker of schizophrenia: A sibling study using tractography-based analysis of the whole brain
  56. A recently-discovered NMDA receptor gene, GRIN3B, is associated with duration mismatch negativity
  57. The tridimensional personality of male heroin users treated with methadone in Taiwan
  58. Identification of novel loci for bipolar I disorder in a multi-stage genome-wide association study
  59. Stable signatures of schizophrenia in the cortical–subcortical–cerebellar network using fMRI of verbal working memory
  60. Olanzapine-Induced Hyponatremia in a Patient with Autism
  61. Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia
  62. Frequency Dependent Alterations in Regional Homogeneity of Baseline Brain Activity in Schizophrenia
  63. A Diagnostic Model Incorporating P50 Sensory Gating and Neuropsychological Tests for Schizophrenia
  64. Aripiprazole for Drug-Naive or Antipsychotic-Short-Exposure Subjects With Ultra-High Risk State and First-Episode Psychosis
  65. Screen for Putative Pre-psychotic States
  66. Development of a brief self-report questionnaire for screening putative pre-psychotic states
  67. Medical costs and vasculometabolic comorbidities among patients with bipolar disorder in Taiwan — A population-based and matched-control study
  68. Frequency-specific alternations in the amplitude of low-frequency fluctuations in schizophrenia
  69. Auditory event-related potential of subjects with suspected pre-psychotic state and first‐episode psychosis
  70. Zotepine-related myopathy in a patient with schizophrenia
  71. Comorbid prevalence of alcohol dependence, substance abuse, and external cause of injury in patients with bipolar disorder in a nationwide representative sample in Taiwan
  72. Neutropenia Associated With the Comedication of Quetiapine and Valproate in 2 Elderly Patients
  73. Medium-term course and outcome of schizophrenia depicted by the sixth-month subtype after an acute episode
  74. Differentiation of Schizophrenia Patients from Healthy Subjects by Mismatch Negativity and Neuropsychological Tests
  75. Poster #238 FACIAL AND PROSODIC EMOTION RECOGNITION DEFICITS PREDICT SPECIFIC DIMENSION OF PSYCHOTIC SYMPTOMS IN SCHIZOPHRENIA
  76. Handedness and schizotypy in non-psychotic relatives of patients with schizophrenia
  77. TIME-FREQUENCY ANALYSIS OF MISMATCH NEGATIVITY IN SCHIZOPHRENIA PATIENTS IN TAIWAN
  78. ANXA7, PPP3CB, DNAJC9, and ZMYND17 Genes at Chromosome 10q22 Associated with the Subgroup of Schizophrenia with Deficits in Attention and Executive Function
  79. MicroRNA Expression Aberration as Potential Peripheral Blood Biomarkers for Schizophrenia
  80. Visuospatial working memory deficits in remitted patients with bipolar disorder: susceptibility to the effects of GABAergic agonists
  81. Performance on the Wisconsin Card Sorting Test in Families of Schizophrenia Patients With Different Familial Loadings
  82. Follow-up of subjects with suspected pre-psychotic state in Taiwan
  83. Thought/Perception Diagnostic Interview Schedule
  84. Acoustic Neuroma Identified After Electroconvulsive Therapy in a Patient With Recurrent Major Depression and Undifferentiated Somatoform Disorder
  85. One‐year post‐hospital medical costs and relapse rates of bipolar disorder patients in Taiwan: a population‐based study
  86. More evidence to support the role of S2 in P50 studies
  87. A case of schizophrenia with dysphagia successfully treated by a multidimensional approach
  88. Corrigendum
  89. Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan
  90. Bupropion-Related Parkinsonism and Dystonia
  91. Clustering by neurocognition for fine mapping of the schizophrenia susceptibility loci on chromosome 6p
  92. Clinical alertness to valproic acid-induced hyperammonemia-two case reports
  93. Genetic variants in COMT and neurocognitive impairment in families of patients with schizophrenia
  94. The multidimensionality of schizotypy in nonpsychotic relatives of patients with schizophrenia and its applications in ordered subsets linkage analysis of schizophrenia
  95. RASD2, MYH9, and CACNG2 Genes at Chromosome 22q12 Associated with the Subgroup of Schizophrenia with Non-Deficit in Sustained Attention and Executive Function
  96. Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents
  97. Impaired Flush Response to Niacin Skin Patch Among Schizophrenia Patients and Their Nonpsychotic Relatives: The Effect of Genetic Loading
  98. HTF9C gene of 22q11.21 region associates with schizophrenia having deficit-sustained attention
  99. Dissociative State and Competence
  100. No association evidence between schizophrenia and dystrobrevin-binding protein 1 (DTNBP1) in Taiwanese families
  101. More evidence supports the association of PPP3CC with schizophrenia
  102. Familial Aggregation in Skin Flush Response to Niacin Patch Among Schizophrenic Patients and Their Nonpsychotic Relatives
  103. Gamma Band Oscillations Reveal Neural Network Cortical Coherence Dysfunction in Schizophrenia Patients
  104. Startle Gating Deficits in a Large Cohort of Patients With Schizophrenia
  105. No association of G72 and d-amino acid oxidase genes with schizophrenia
  106. More severe sustained attention deficits in nonpsychotic siblings of multiplex schizophrenia families than in those of simplex ones
  107. Re-examining sustained attention deficits as vulnerability indicators for schizophrenia: Stability in the long term course
  108. Association evidence of schizophrenia with distal genomic region of NOTCH4 in Taiwanese families
  109. A Single Nucleotide Polymorphism Fine Mapping Study of Chromosome 1q42.1 Reveals the Vulnerability Genes for Schizophrenia, GNPAT and DISC1: Association with Impairment of Sustained Attention
  110. Evaluation ofRGS4 as a candidate gene for schizophrenia
  111. Effects of Background and Prepulse Characteristics on Prepulse Inhibition and Facilitation: Implications for Neuropsychiatric Research
  112. Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population
  113. Patterns and Clinical Correlates of Neuropsychologic Deficits in Patients with Schizophrenia
  114. Dual-modality impairment of implicit learning of letter-strings versus color-patterns in patients with schizophrenia
  115. Memory impairment and auditory evoked potential gating deficit in schizophrenia
  116. Neuropsychological evaluation on three subtypes of schizophrenia
  117. Impairment of color-pattern implicit learning and P50 AEP gating in schizophrenic patients: A 3D brain mapping study